Camp4 Therapeutics Stock Rockets 119% With 8-Day Winning Streak
Camp4 Therapeutics (CAMP) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 119% return. The company has gained about $106 Mil in value over the last 8 days, with its current market capitalization at about $194 Mil. The stock remains 36.6% above its value at the end of 2024. This compares with year-to-date returns of 14.3% for the S&P 500.
Camp4 Therapeutics’ recent streak, seeing shares surge, is largely fueled by a significant private placement bolstering its balance sheet and advancing the lead CMP-002 program for SYNGAP1-related disorders into GLP toxicology studies, signaling crucial pipeline progress alongside sustained analyst confidence.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are a few things to fear in CAMP stock given its overall Weak operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Very Unattractive (see Buy or Sell CAMP).
For quick background, CAMP is a clinical-stage biopharmaceutical company developing regulatory RNA-based therapeutics to upregulate gene expression and restore protein levels for treating various genetic diseases.
- Get Paid 8.7% to Buy WYNN at a 30% Discount – Here’s How
- What Could Go Wrong With PepsiCo Stock?
- Cash Rich, Low Price – Coursera Stock to Break Out?
- Momentum Meets Value: Sterling Infrastructure Stock Could Be A Good Buy
- Adobe Stock Pullback: A Chance to Ride the Uptrend
- Is Lululemon Athletica Stock Poised for a Rally?
Comparing CAMP Stock Returns With The S&P 500
The following table summarizes the return for CAMP stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CAMP | S&P 500 |
|---|---|---|
| 1D | 1.7% | -1.2% |
| 8D (Current Streak) | 119.4% | -2.2% |
| 1M (21D) | 78.7% | 0.7% |
| 3M (63D) | 185.2% | 1.3% |
| YTD 2025 | 36.6% | 14.3% |
| 2024 | 23.3% | |
| 2023 | 24.2% | |
| 2022 | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 24 S&P constituents with 3 days or more of consecutive gains and 63 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 17 |
| 4D | 2 | 35 |
| 5D | 2 | 9 |
| 6D | 5 | 0 |
| 7D or more | 6 | 2 |
| Total >=3 D | 24 | 63 |
Key Financials for Camp4 Therapeutics (CAMP)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.3 Mil | $0.7 Mil |
| Operating Income | $-51.9 Mil | $-53.1 Mil |
| Net Income | $-49.3 Mil | $-51.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.5 Mil | $0.8 Mil |
| Operating Income | $-13.0 Mil | $-13.2 Mil |
| Net Income | $-12.6 Mil | $-15.1 Mil |
While CAMP stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.